{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:37Z","timestamp":1788243397161,"version":"build-2803163510"},"reference-count":200,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02353-7","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:38:16Z","timestamp":1786124296000},"page":"1513-1533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation"],"prefix":"10.1007","volume":"86","author":[{"given":"Shrey","family":"Sindhwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Gehlaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harveen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Juloori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5980-4973","authenticated-orcid":false,"given":"Noura J.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"2353_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"2353_CR2","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2025.0560","volume":"333","author":"SY Kim","year":"2025","unstructured":"Kim SY, Park HS, Chiang AC. Small cell lung cancer: a review. JAMA. 2025;333:1906\u201317. https:\/\/doi.org\/10.1001\/jama.2025.0560.","journal-title":"JAMA"},{"issue":"3","key":"2353_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70608","volume":"14","author":"D Uprety","year":"2025","unstructured":"Uprety D, Seaton R, Niroula A, Hadid T, Parikh K, Ruterbusch JJ. Trends in the incidence and survival outcomes in patients with small cell lung cancer in the United States: an analysis of the SEER database. Cancer Med. 2025;14(3): e70608. https:\/\/doi.org\/10.1002\/cam4.70608.","journal-title":"Cancer Med."},{"key":"2353_CR4","unstructured":"American Cancer Society. Cancer facts and figures 2025. American Cancer Society; 2025."},{"key":"2353_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","volume":"18","author":"Q Wang","year":"2023","unstructured":"Wang Q, G\u00fcm\u00fc\u015f ZH, Colarossi C, Memeo L, Wang X, Kong CY, et al. SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol. 2023;18:31\u201346. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.002.","journal-title":"J Thorac Oncol"},{"key":"2353_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pccm.2023.10.005","volume":"2","author":"Y Yang","year":"2024","unstructured":"Yang Y, Fan S. Small cell lung cancer transformations from non-small cell lung cancer: Biological mechanism and clinical relevance. Chin Med J Pulm Crit Care Med. 2024;2:42\u20137. https:\/\/doi.org\/10.1016\/j.pccm.2023.10.005.","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"2353_CR7","unstructured":"National Comprehensive Cancer Network. Small cell lung cancer. NCCN clinical practice guidelines in oncology 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Accessed 25 Nov 2025."},{"key":"2353_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040820","author":"MG Raso","year":"2021","unstructured":"Raso MG, Bota-Rabassedas N, Wistuba II. Pathology and classification of SCLC. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040820.","journal-title":"Cancers (Basel)"},{"key":"2353_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2022","unstructured":"Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022;17:362\u201387. https:\/\/doi.org\/10.1016\/j.jtho.2021.11.003.","journal-title":"J Thorac Oncol"},{"key":"2353_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00268-010-0784-x","volume":"35","author":"G Chen","year":"2011","unstructured":"Chen G, Wang Z, Liu X-Y, Liu F-Y. High-level CXCR4 expression correlates with brain-specific metastasis of non-small cell lung cancer. World J Surg. 2011;35:56\u201361. https:\/\/doi.org\/10.1007\/s00268-010-0784-x.","journal-title":"World J Surg"},{"key":"2353_CR11","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.cllc.2016.01.003","volume":"17","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, et al. Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. Clin Lung Cancer. 2016;17:e121\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2016.01.003.","journal-title":"Clin Lung Cancer"},{"key":"2353_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100871","volume":"6","author":"SM Lim","year":"2025","unstructured":"Lim SM, Shim JSG, Shim HS, Tanizaki J, Nutzinger J, Cho BC, et al. What Is on the horizon for the diagnosis and treatment of SCLC and large cell neuroendocrine cancer? JTO Clin Res Rep. 2025;6:100871. https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100871.","journal-title":"JTO Clin Res Rep"},{"key":"2353_CR13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine MK, Hsieh M-S, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15:1823\u201335. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.009.","journal-title":"J Thorac Oncol"},{"key":"2353_CR14","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1097\/PAS.0000000000000916","volume":"41","author":"LM Rooper","year":"2017","unstructured":"Rooper LM, Sharma R, Li QK, Illei PB, Westra WH. INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am J Surg Pathol. 2017;41:1561\u20139. https:\/\/doi.org\/10.1097\/PAS.0000000000000916.","journal-title":"Am J Surg Pathol"},{"key":"2353_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","volume":"35","author":"N Rekhtman","year":"2022","unstructured":"Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2022;35:36\u201350. https:\/\/doi.org\/10.1038\/s41379-021-00943-2.","journal-title":"Mod Pathol"},{"key":"2353_CR16","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1101\/gad.328336.119","volume":"33","author":"MG Oser","year":"2019","unstructured":"Oser MG, Sabet AH, Gao W, Chakraborty AA, Schinzel AC, Jennings RB, et al. The KDM5A\/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes Dev. 2019;33:1718\u201338. https:\/\/doi.org\/10.1101\/gad.328336.119.","journal-title":"Genes Dev"},{"key":"2353_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346\u201360. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.014.","journal-title":"Cancer Cell"},{"key":"2353_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289\u201397. https:\/\/doi.org\/10.1038\/s41568-019-0133-9.","journal-title":"Nat Rev Cancer"},{"key":"2353_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/cas.15606","volume":"114","author":"H Wang","year":"2023","unstructured":"Wang H, Wu S, Li Z, Zhang C, Shang X, Zhao C, et al. Molecular subtyping of small\u2010cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies. Cancer Sci. 2023;114:665\u201379. https:\/\/doi.org\/10.1111\/cas.15606.","journal-title":"Cancer Sci"},{"key":"2353_CR20","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.celrep.2016.06.081","volume":"16","author":"MD Borromeo","year":"2016","unstructured":"Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 2016;16:1259\u201372. https:\/\/doi.org\/10.1016\/j.celrep.2016.06.081.","journal-title":"Cell Rep"},{"key":"2353_CR21","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10:1240\u20132. https:\/\/doi.org\/10.1097\/JTO.0000000000000663.","journal-title":"J Thorac Oncol"},{"key":"2353_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozreti\u0107 L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47\u201353. https:\/\/doi.org\/10.1038\/nature14664.","journal-title":"Nature"},{"key":"2353_CR23","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","volume":"39","author":"JM Chan","year":"2021","unstructured":"Chan JM, Quintanal-Villalonga \u00c1, Gao VR, Xie Y, Allaj V, Chaudhary O, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39:1479-96.e18. https:\/\/doi.org\/10.1016\/j.ccell.2021.09.008.","journal-title":"Cancer Cell"},{"key":"2353_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ccell.2017.08.006","volume":"32","author":"M Vaz","year":"2017","unstructured":"Vaz M, Hwang SY, Kagiampakis I, Phallen J, Patil A, et al. Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations. Cancer Cell. 2017;32:360\u201376. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.006.","journal-title":"Cancer Cell"},{"key":"2353_CR25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.21037\/atm.2020.02.177","volume":"8","author":"NJ Robinson","year":"2020","unstructured":"Robinson NJ, Parker KA, Schiemann WP. Epigenetic plasticity in metastatic dormancy: mechanisms and therapeutic implications. Ann Transl Med. 2020;8:903. https:\/\/doi.org\/10.21037\/atm.2020.02.177.","journal-title":"Ann Transl Med"},{"key":"2353_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2020.11.006","volume":"83","author":"P Khan","year":"2022","unstructured":"Khan P, Siddiqui JA, Maurya SK, Lakshmanan I, Jain M, Ganti AK, et al. Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Semin Cancer Biol. 2022;83:57\u201376. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.006.","journal-title":"Semin Cancer Biol"},{"key":"2353_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2217\/epi.09.33","volume":"1","author":"M Ehrlich","year":"2009","unstructured":"Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1:239\u201359. https:\/\/doi.org\/10.2217\/epi.09.33.","journal-title":"Epigenomics"},{"key":"2353_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.2396","volume":"44","author":"M Peifer","year":"2012","unstructured":"Peifer M, Fern\u00e1ndez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104\u201310. https:\/\/doi.org\/10.1038\/ng.2396.","journal-title":"Nat Genet"},{"key":"2353_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/jnci\/93.9.691","volume":"93","author":"DG Burbee","year":"2001","unstructured":"Burbee DG, Forgacs E, Z\u00f6chbauer-M\u00fcller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001;93:691\u20139. https:\/\/doi.org\/10.1093\/jnci\/93.9.691.","journal-title":"J Natl Cancer Inst"},{"key":"2353_CR30","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/onc.2015.38","volume":"34","author":"JT Poirier","year":"2015","unstructured":"Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. 2015;34:5869\u201378. https:\/\/doi.org\/10.1038\/onc.2015.38.","journal-title":"Oncogene"},{"key":"2353_CR31","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1038\/onc.2012.362","volume":"32","author":"S Kalari","year":"2013","unstructured":"Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene. 2013;32:3559\u201368. https:\/\/doi.org\/10.1038\/onc.2012.362.","journal-title":"Oncogene"},{"key":"2353_CR32","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1016\/j.celrep.2018.08.062","volume":"24","author":"BA Smith","year":"2018","unstructured":"Smith BA, Balanis NG, Nanjundiah A, Sheu KM, Tsai BL, Zhang Q, et al. A human adult stem cell signature marks aggressive variants across epithelial cancers. Cell Rep. 2018;24:3353-66.e5. https:\/\/doi.org\/10.1016\/j.celrep.2018.08.062.","journal-title":"Cell Rep"},{"key":"2353_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3892\/etm.2017.4476","volume":"14","author":"H Lu","year":"2017","unstructured":"Lu H, Qin J, Xu H, Han N, Xie F, Mao WO. O6-methyl-guanine-DNA methyltransferase methylation and IDH1\/2 mutation in small cell lung cancer. Exp Ther Med. 2017;14:398\u2013402. https:\/\/doi.org\/10.3892\/etm.2017.4476.","journal-title":"Exp Ther Med"},{"key":"2353_CR34","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1038\/s41388-020-1386-1","volume":"39","author":"M Wang","year":"2020","unstructured":"Wang M, Long K, Li E, Li L, Li B, Ci S, et al. DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation. Oncogene. 2020;39:5507\u201319. https:\/\/doi.org\/10.1038\/s41388-020-1386-1.","journal-title":"Oncogene"},{"key":"2353_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jtho.2016.12.011","volume":"12","author":"A Augert","year":"2017","unstructured":"Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, et al. Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D\/MLL2: CALGB 151111 (Alliance). J Thorac Oncol. 2017;12:704\u201313. https:\/\/doi.org\/10.1016\/j.jtho.2016.12.011.","journal-title":"J Thorac Oncol"},{"key":"2353_CR36","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.trecan.2024.07.008","volume":"10","author":"E Redin","year":"2024","unstructured":"Redin E, Quintanal-Villalonga \u00c1, Rudin CM. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends Cancer. 2024;10:935\u201346. https:\/\/doi.org\/10.1016\/j.trecan.2024.07.008.","journal-title":"Trends Cancer"},{"key":"2353_CR37","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","volume":"21","author":"T Sen","year":"2024","unstructured":"Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024;21:610\u201327. https:\/\/doi.org\/10.1038\/s41571-024-00914-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"2353_CR38","doi-asserted-by":"publisher","unstructured":"George J, Lim JS, Peifer M, Sage J, Thomas R. Abstract LB-168: comprehensive genomic characterization of small cell lung cancer. Cancer Res 2015;75:LB168. https:\/\/doi.org\/10.1158\/1538-7445.am2015-lb-168.","DOI":"10.1158\/1538-7445.am2015-lb-168"},{"key":"2353_CR39","doi-asserted-by":"publisher","first-page":"31014","DOI":"10.18632\/oncotarget.8826","volume":"7","author":"FP Fiorentino","year":"2016","unstructured":"Fiorentino FP, Tokg\u00fcn E, Sol\u00e9-S\u00e1nchez S, Giampaolo S, Tokg\u00fcn O, Jauset T, et al. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget. 2016;7:31014\u201328. https:\/\/doi.org\/10.18632\/oncotarget.8826.","journal-title":"Oncotarget"},{"key":"2353_CR40","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/annonc\/mdw005","volume":"27","author":"A Dowlati","year":"2016","unstructured":"Dowlati A, Lipka MB, McColl K, Dabir S, Behtaj M, Kresak A, et al. Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol. 2016;27:642\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdw005.","journal-title":"Ann Oncol"},{"key":"2353_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.lungcan.2014.02.013","volume":"84","author":"K Wakuda","year":"2014","unstructured":"Wakuda K, Kenmotsu H, Serizawa M, Koh Y, Isaka M, Takahashi S, et al. Molecular profiling of small cell lung cancer in a Japanese cohort. Lung Cancer. 2014;84:139\u201344. https:\/\/doi.org\/10.1016\/j.lungcan.2014.02.013.","journal-title":"Lung Cancer"},{"key":"2353_CR42","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s13104-015-1675-x","volume":"8","author":"F Abdelraouf","year":"2015","unstructured":"Abdelraouf F, Sharp A, Maurya M, Mair D, Wotherspoon A, Leary A, et al. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. BMC Res Notes. 2015;8:688. https:\/\/doi.org\/10.1186\/s13104-015-1675-x.","journal-title":"BMC Res Notes"},{"key":"2353_CR43","doi-asserted-by":"publisher","unstructured":"Wang Z, Jiang Z, Lu H. Molecular genetic profiling of small cell lung carcinoma in a Chinese cohort. Transl Cancer Res. 2019;8:255\u201361. https:\/\/doi.org\/10.21037\/tcr.2019.01.26.","DOI":"10.21037\/tcr.2019.01.26"},{"key":"2353_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fonc.2019.00254","volume":"9","author":"AF Cardona","year":"2019","unstructured":"Cardona AF, Rojas L, Zatarain-Barr\u00f3n ZL, Ruiz-Pati\u00f1o A, Ricaurte L, Corrales L, et al. Multigene mutation profiling and clinical characteristics of small-cell lung cancer in never-smokers vs. heavy smokers (Geno1.3-CLICaP). Front Oncol. 2019;9:254. https:\/\/doi.org\/10.3389\/fonc.2019.00254.","journal-title":"Front Oncol"},{"key":"2353_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/1878-0261.12673","volume":"15","author":"A Ogino","year":"2021","unstructured":"Ogino A, Choi J, Lin M, Wilkens MK, Calles A, Xu M, et al. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never\/light smokers identifies therapeutically targetable alterations. Mol Oncol. 2021;15:27\u201342. https:\/\/doi.org\/10.1002\/1878-0261.12673.","journal-title":"Mol Oncol"},{"key":"2353_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/annonc\/mdu504","volume":"26","author":"J-M Sun","year":"2015","unstructured":"Sun J-M, Choi Y-L, Ji JH, Ahn JS, Kim K-M, Han J, et al. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann Oncol. 2015;26:161\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdu504.","journal-title":"Ann Oncol"},{"key":"2353_CR47","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.chest.2020.04.068","volume":"158","author":"A Thomas","year":"2020","unstructured":"Thomas A, Mian I, Tlemsani C, Pongor L, Takahashi N, Maignan K, et al. Clinical and genomic characteristics of small cell lung cancer in never smokers: results from a retrospective multicenter cohort study. Chest. 2020;158:1723\u201333. https:\/\/doi.org\/10.1016\/j.chest.2020.04.068.","journal-title":"Chest"},{"key":"2353_CR48","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41467-022-29794-4","volume":"13","author":"R Caeser","year":"2022","unstructured":"Caeser R, Egger JV, Chavan S, Socci ND, Jones CB, Kombak FE, et al. Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nat Commun. 2022;13:2144. https:\/\/doi.org\/10.1038\/s41467-022-29794-4.","journal-title":"Nat Commun"},{"key":"2353_CR49","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/JTO.0000000000000142","volume":"9","author":"AM Varghese","year":"2014","unstructured":"Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, et al. Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014;9:892\u20136. https:\/\/doi.org\/10.1097\/JTO.0000000000000142.","journal-title":"J Thorac Oncol"},{"key":"2353_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010224","author":"L Zullo","year":"2023","unstructured":"Zullo L, Dall\u2019Olio FG, Rossi G, Dellepiane C, Barletta G, Bennicelli E, et al. Molecular and genetic advances in small cell lung cancer landscape: from homogeneity to diversity. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms25010224.","journal-title":"Int J Mol Sci"},{"key":"2353_CR51","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/2159-8290.CD-22-0620","volume":"13","author":"S Sivakumar","year":"2023","unstructured":"Sivakumar S, Moore JA, Montesion M, Sharaf R, Lin DI, Col\u00f3n CI, et al. Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation. Cancer Discov. 2023;13:1572\u201391. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0620.","journal-title":"Cancer Discov"},{"key":"2353_CR52","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-22-1115","volume":"28","author":"CA Febres-Aldana","year":"2022","unstructured":"Febres-Aldana CA, Chang JC, Ptashkin R, Wang Y, Gedvilaite E, Baine MK, et al. Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset. Clin Cancer Res. 2022;28:4702\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1115.","journal-title":"Clin Cancer Res"},{"key":"2353_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cllc.2025.03.011","volume":"26","author":"MS Oh","year":"2025","unstructured":"Oh MS, Garon EB, Lisberg AE, Cummings AL, Barrett A, Ashok A, et al. Brief report: the genomic landscape of small cell lung cancer in never-smoking patients. Clin Lung Cancer. 2025;26:434-9.e3. https:\/\/doi.org\/10.1016\/j.cllc.2025.03.011.","journal-title":"Clin Lung Cancer"},{"key":"2353_CR54","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1038\/s41467-018-06162-9","volume":"9","author":"AH Wagner","year":"2018","unstructured":"Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun. 2018;9:3787. https:\/\/doi.org\/10.1038\/s41467-018-06162-9.","journal-title":"Nat Commun"},{"key":"2353_CR55","unstructured":"U.S. Preventative Services Task Force. Lung cancer: screening. US Preventative Services Task Force 2021. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lung-cancer-screening. Accessed 2 Dec 2025."},{"key":"2353_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"DR Aberle","year":"2011","unstructured":"National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395\u2013409. https:\/\/doi.org\/10.1056\/NEJMoa1102873.","journal-title":"N Engl J Med"},{"key":"2353_CR57","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.chest.2018.07.029","volume":"154","author":"A Thomas","year":"2018","unstructured":"Thomas A, Pattanayak P, Szabo E, Pinsky P. Characteristics and outcomes of small cell lung cancer detected by CT screening. Chest. 2018;154:1284\u201390. https:\/\/doi.org\/10.1016\/j.chest.2018.07.029.","journal-title":"Chest"},{"key":"2353_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jtho.2015.10.014","volume":"11","author":"M Silva","year":"2016","unstructured":"Silva M, Galeone C, Sverzellati N, Marchian\u00f2 A, Calareso G, Sestini S, et al. Screening with low-dose computed tomography does not improve survival of small cell lung cancer. J Thorac Oncol. 2016;11:187\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2015.10.014.","journal-title":"J Thorac Oncol"},{"key":"2353_CR59","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/JTO.0b013e31820c2f2e","volume":"6","author":"S Cuffe","year":"2011","unstructured":"Cuffe S, Moua T, Summerfield R, Roberts H, Jett J, Shepherd FA. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol. 2011;6:818\u201322. https:\/\/doi.org\/10.1097\/JTO.0b013e31820c2f2e.","journal-title":"J Thorac Oncol"},{"key":"2353_CR60","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/1097-0142(19860215)57:4<847::aid-cncr2820570427>3.0.co;2-h","volume":"57","author":"JP Sculier","year":"1986","unstructured":"Sculier JP, Evans WK, Feld R, DeBoer G, Payne DG, Shepherd FA, et al. Superior vena caval obstruction syndrome in small cell lung cancer. Cancer. 1986;57:847\u201351. https:\/\/doi.org\/10.1002\/1097-0142(19860215)57:4%3c847::aid-cncr2820570427%3e3.0.co;2-h.","journal-title":"Cancer"},{"key":"2353_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001021","author":"A Ruano-Ravi\u00f1a","year":"2020","unstructured":"Ruano-Ravi\u00f1a A, Provencio M, De Juan C. Lung cancer symptoms at diagnosis: results of a nationwide registry study. ESMO Open. 2020. https:\/\/doi.org\/10.1136\/esmoopen-2020-001021.","journal-title":"ESMO Open"},{"key":"2353_CR62","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1200\/JCO.2008.17.5133","volume":"26","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer MJ, Wirtz PW, Willems LNA, van Kralingen KW, Smitt PAES, Verschuuren JJGM. Screening for small-cell lung cancer: a follow-up study of patients with Lambert\u2013Eaton myasthenic syndrome. J Clin Oncol. 2008;26:4276\u201381. https:\/\/doi.org\/10.1200\/JCO.2008.17.5133.","journal-title":"J Clin Oncol"},{"key":"2353_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1177125PubMedGoogleScholar","author":"Y Li","year":"2023","unstructured":"Li Y, Li C, Qi X, Yu L, Lin L. Management of small cell lung cancer complicated with paraneoplastic Cushing\u2019s syndrome: a systematic literature review. Front Endocrinol (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1177125PubMedGoogleScholar.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2353_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.671951PubMedGoogleScholar","author":"E Bartalis","year":"2021","unstructured":"Bartalis E, Gergics M, Tinusz B. Prevalence and prognostic significance of hyponatremia in patients with lung cancer: systematic review and meta-analysis. Front Med (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fmed.2021.671951PubMedGoogleScholar.","journal-title":"Front Med (Lausanne)"},{"key":"2353_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/ITT.S31971","volume":"2","author":"SE Briggs","year":"2013","unstructured":"Briggs SE, Gozzard P, Talbot DC. The association between Lambert\u2013Eaton myasthenic syndrome and small cell lung carcinoma. ImmunoTargets Ther. 2013;2:31\u20137. https:\/\/doi.org\/10.2147\/ITT.S31971.","journal-title":"ImmunoTargets Ther"},{"key":"2353_CR66","doi-asserted-by":"publisher","first-page":"e142S","DOI":"10.1378\/chest.12-2353","volume":"143","author":"MP Rivera","year":"2013","unstructured":"Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e142S-e165S. https:\/\/doi.org\/10.1378\/chest.12-2353.","journal-title":"Chest"},{"key":"2353_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1102\/1470-7330.2011.0036","volume":"11","author":"GP Kalemkerian","year":"2012","unstructured":"Kalemkerian GP. Staging and imaging of small cell lung cancer. Cancer Imaging. 2012;11:253\u20138. https:\/\/doi.org\/10.1102\/1470-7330.2011.0036.","journal-title":"Cancer Imaging"},{"key":"2353_CR68","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archinte.168.14.1541","volume":"168","author":"KG Chee","year":"2008","unstructured":"Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN Jr. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008;168:1541\u20139. https:\/\/doi.org\/10.1001\/archinte.168.14.1541.","journal-title":"Arch Intern Med"},{"key":"2353_CR69","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","volume":"327","author":"JP Pignon","year":"1992","unstructured":"Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618\u201324. https:\/\/doi.org\/10.1056\/NEJM199212033272302.","journal-title":"N Engl J Med"},{"key":"2353_CR70","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1056\/NEJM199901283400403","volume":"340","author":"AT Turrisi 3rd","year":"1999","unstructured":"Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265\u201371. https:\/\/doi.org\/10.1056\/NEJM199901283400403.","journal-title":"N Engl J Med"},{"key":"2353_CR71","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","volume":"10","author":"CB Simone 2nd","year":"2020","unstructured":"Simone CB 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, et al. Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020;10:158\u201373. https:\/\/doi.org\/10.1016\/j.prro.2020.02.009.","journal-title":"Pract Radiat Oncol"},{"key":"2353_CR72","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.012492","author":"LA Hatfield","year":"2016","unstructured":"Hatfield LA, Huskamp HA, Lamont EB. Survival and toxicity after cisplatin plus etoposide versus carboplatin plus etoposide for extensive-stage small-cell lung cancer in elderly patients. J Oncol Pract. 2016. https:\/\/doi.org\/10.1200\/JOP.2016.012492.","journal-title":"J Oncol Pract"},{"key":"2353_CR73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.4905","author":"A Rossi","year":"2012","unstructured":"Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012. https:\/\/doi.org\/10.1200\/JCO.2011.40.4905.","journal-title":"J Clin Oncol"},{"key":"2353_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603810","author":"H Okamoto","year":"2007","unstructured":"Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007. https:\/\/doi.org\/10.1038\/sj.bjc.6603810.","journal-title":"Br J Cancer"},{"key":"2353_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058931","author":"DV Skarlos","year":"1994","unstructured":"Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer A Hellenic Co-operative Oncology Group study. Ann Oncol. 1994. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058931.","journal-title":"Ann Oncol"},{"key":"2353_CR76","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","volume":"18","author":"C Faivre-Finn","year":"2017","unstructured":"Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(17)30318-2.","journal-title":"Lancet Oncol"},{"key":"2353_CR77","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391:1313\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2404873.","journal-title":"N Engl J Med"},{"key":"2353_CR78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01569","author":"KA Higgins","year":"2026","unstructured":"Higgins KA, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, et al. Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: results of NRG oncology\/alliance LU005. J Clin Oncol. 2026. https:\/\/doi.org\/10.1200\/JCO-25-01569.","journal-title":"J Clin Oncol"},{"key":"2353_CR79","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1200\/JCO.1993.11.2.336","volume":"11","author":"N Murray","year":"1993","unstructured":"Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11:336\u201344. https:\/\/doi.org\/10.1200\/JCO.1993.11.2.336.","journal-title":"J Clin Oncol"},{"key":"2353_CR80","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1200\/JCO.2004.01.178","volume":"22","author":"DB Fried","year":"2004","unstructured":"Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22:4837\u201345. https:\/\/doi.org\/10.1200\/JCO.2004.01.178.","journal-title":"J Clin Oncol"},{"key":"2353_CR81","unstructured":"Radiation Therapy for Small Cell Lung Cancer n.d. https:\/\/www.guidelinecentral.com\/guideline\/8729. Accessed 2 May 2026."},{"key":"2353_CR82","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ijrobp.2003.10.021","volume":"59","author":"JA Bogart","year":"2004","unstructured":"Bogart JA, Herndon JE 2nd, Lyss AP, Watson D, Miller AA, Lee ME, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004;59:460\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.10.021.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2353_CR83","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3816\/CLC.2005.n.007","volume":"6","author":"AW Blackstock","year":"2005","unstructured":"Blackstock AW, Bogart JA, Matthews C, Lovato JF, McCoy T, Livengood K, et al. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial. Clin Lung Cancer. 2005;6:287\u201392. https:\/\/doi.org\/10.3816\/CLC.2005.n.007.","journal-title":"Clin Lung Cancer"},{"key":"2353_CR84","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1200\/JCO.1999.17.9.2681","volume":"17","author":"JA Bonner","year":"1999","unstructured":"Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17:2681\u201391. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2681.","journal-title":"J Clin Oncol"},{"key":"2353_CR85","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S2213-2600(24)00189-9","volume":"12","author":"J Yu","year":"2024","unstructured":"Yu J, Jiang L, Zhao L, Yang X, Wang X, Yang D, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. 2024;12:799\u2013809. https:\/\/doi.org\/10.1016\/S2213-2600(24)00189-9.","journal-title":"Lancet Respir Med"},{"key":"2353_CR86","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jtho.2025.04.007","volume":"20","author":"BH Gr\u00f8nberg","year":"2025","unstructured":"Gr\u00f8nberg BH, Killingberg KT, Fl\u00f8tten \u00d8, Bjaan\u00e6s MM, Brustugun OT, Madebo T, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy in limited-stage SCLC: final survival data, long-term toxicity, and relapse patterns in a randomized, open-label, phase II trial. J Thorac Oncol. 2025;20:1108\u201319. https:\/\/doi.org\/10.1016\/j.jtho.2025.04.007.","journal-title":"J Thorac Oncol"},{"key":"2353_CR87","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/nejm199908123410703","volume":"341","author":"A Aup\u00e9rin","year":"1999","unstructured":"Aup\u00e9rin A, Arriagada R, Pignon JP, Le P\u00e9choux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341:476\u201384. https:\/\/doi.org\/10.1056\/nejm199908123410703.","journal-title":"N Engl J Med"},{"key":"2353_CR88","doi-asserted-by":"publisher","first-page":"433","DOI":"10.7150\/jca.21465","volume":"9","author":"Y Yang","year":"2018","unstructured":"Yang Y, Zhang D, Zhou X, Bao W, Ji Y, Sheng L, et al. Prophylactic cranial irradiation in resected small cell lung cancer: a systematic review with meta-analysis. J Cancer. 2018;9:433\u20139. https:\/\/doi.org\/10.7150\/jca.21465.","journal-title":"J Cancer"},{"key":"2353_CR89","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jtho.2020.12.024","volume":"16","author":"JSA Belderbos","year":"2021","unstructured":"Belderbos JSA, De Ruysscher DKM, De Jaeger K, Koppe F, Lambrecht MLF, Lievens YN, et al. Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675). J Thorac Oncol. 2021;16:840\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2020.12.024.","journal-title":"J Thorac Oncol"},{"key":"2353_CR90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00221","author":"V Gondi","year":"2025","unstructured":"Gondi V, Pugh SL, Mehta MP, Wefel JS, Tom\u00e9 WA, Sun AY, et al. Hippocampal avoidance during prophylactic cranial irradiation for patients with small cell lung cancer: randomized phase II\/III trial NRG-CC003. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-25-00221.","journal-title":"J Clin Oncol"},{"key":"2353_CR91","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cllc.2018.12.019","volume":"20","author":"J Pacheco","year":"2019","unstructured":"Pacheco J, Bunn PA. Advancements in small-cell lung cancer: the changing landscape following IMpower-133. Clin Lung Cancer. 2019;20:148-60.e2. https:\/\/doi.org\/10.1016\/j.cllc.2018.12.019.","journal-title":"Clin Lung Cancer"},{"key":"2353_CR92","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.resinv.2025.05.013","volume":"63","author":"S Niho","year":"2025","unstructured":"Niho S. Treatment of small cell lung cancer; advances and future prospects. Respir Investig. 2025;63:680\u20135. https:\/\/doi.org\/10.1016\/j.resinv.2025.05.013.","journal-title":"Respir Investig"},{"key":"2353_CR93","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"key":"2353_CR94","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01055.","journal-title":"J Clin Oncol"},{"key":"2353_CR95","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet"},{"key":"2353_CR96","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.cllc.2025.08.001","volume":"26","author":"N Reinmuth","year":"2025","unstructured":"Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study. Clin Lung Cancer. 2025;26:626\u201341. https:\/\/doi.org\/10.1016\/j.cllc.2025.08.001.","journal-title":"Clin Lung Cancer"},{"key":"2353_CR97","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7:100408. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100408.","journal-title":"ESMO Open"},{"key":"2353_CR98","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.jtocrr.2024.100744","volume":"6","author":"L Moliner","year":"2025","unstructured":"Moliner L, Zellweger N, Schmid S, Bertschinger M, Waibel C, Cerciello F, et al. First-line chemo-immunotherapy in SCLC: outcomes of a binational real-world study. JTO Clin Res Rep. 2025;6:100744. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100744.","journal-title":"JTO Clin Res Rep"},{"key":"2353_CR99","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","volume":"405","author":"L Paz-Ares","year":"2025","unstructured":"Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025;405:2129\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(25)01011-6.","journal-title":"Lancet"},{"key":"2353_CR100","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/bjc.2017.205","volume":"117","author":"C Belgiovine","year":"2017","unstructured":"Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017;117:628\u201338. https:\/\/doi.org\/10.1038\/bjc.2017.205.","journal-title":"Br J Cancer"},{"key":"2353_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101944","volume":"6","author":"S Chakraborty","year":"2025","unstructured":"Chakraborty S, Sen U, Ventura K, Jethalia V, Coleman C, Sridhar S, et al. Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Cell Rep Med. 2025;6: 101944. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101944.","journal-title":"Cell Rep Med"},{"key":"2353_CR102","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/S0140-6736(25)01145-6","volume":"405","author":"NJ Choudhury","year":"2025","unstructured":"Choudhury NJ, Garassino MC. Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer. Lancet. 2025;405:2104\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(25)01145-6.","journal-title":"Lancet"},{"key":"2353_CR103","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","volume":"12","author":"EM Gore","year":"2017","unstructured":"Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017;12:1561\u201370. https:\/\/doi.org\/10.1016\/j.jtho.2017.06.015.","journal-title":"J Thorac Oncol"},{"key":"2353_CR104","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa071780","volume":"357","author":"B Slotman","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664\u201372. https:\/\/doi.org\/10.1056\/NEJMoa071780.","journal-title":"N Engl J Med"},{"key":"2353_CR105","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cllc.2015.09.007","volume":"17","author":"DA Palma","year":"2016","unstructured":"Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer. 2016;17:239\u201344. https:\/\/doi.org\/10.1016\/j.cllc.2015.09.007.","journal-title":"Clin Lung Cancer"},{"key":"2353_CR106","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(14)61085-0.","journal-title":"Lancet"},{"key":"2353_CR107","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaoncol.2020.1271","volume":"6","author":"CG Rusthoven","year":"2020","unstructured":"Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, et al. Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: the FIRE-SCLC cohort study. JAMA Oncol. 2020;6:1028\u201337. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1271.","journal-title":"JAMA Oncol"},{"key":"2353_CR108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.radonc.2021.06.026","volume":"162","author":"GA Viani","year":"2021","unstructured":"Viani GA, Gouveia AG, Louie AV, Moraes FY. Stereotactic radiosurgery for brain metastases from small cell lung cancer without prior whole-brain radiotherapy: a meta-analysis. Radiother Oncol. 2021;162:45\u201351. https:\/\/doi.org\/10.1016\/j.radonc.2021.06.026.","journal-title":"Radiother Oncol"},{"key":"2353_CR109","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","volume":"18","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(17)30230-9.","journal-title":"Lancet Oncol"},{"key":"2353_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100305","volume":"3","author":"K Kunimasa","year":"2022","unstructured":"Kunimasa K, Hirotsu Y, Amemiya K, Nakamura H, Nishino K, Honma K, et al. Loss of heterozygosity induces de novo SCLC formation in EGFR-mutated lung adenocarcinoma: a case report. JTO Clin Res Rep. 2022;3:100305. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100305.","journal-title":"JTO Clin Res Rep"},{"key":"2353_CR111","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14:1784\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.002.","journal-title":"J Thorac Oncol"},{"key":"2353_CR112","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.jtho.2022.07.084","volume":"17","author":"J Huang","year":"2022","unstructured":"Huang J, Huang W, Wang Q, Zhang C, Ni S, Sun D. MA02.05 dynamic mutation profiles of SCLC transformation in NSCLC patients harboring concurrent EGFR\/TP53\/RB1 mutations. J Thorac Oncol. 2022;17:S48. https:\/\/doi.org\/10.1016\/j.jtho.2022.07.084.","journal-title":"J Thorac Oncol"},{"key":"2353_CR113","doi-asserted-by":"publisher","first-page":"642190","DOI":"10.3389\/fonc.2021.642190","volume":"11","author":"A Leonetti","year":"2021","unstructured":"Leonetti A, Minari R, Mazzaschi G, Gnetti L, La Monica S, Alfieri R, et al. Small cell lung cancer transformation as a resistance mechanism to Osimertinib in epidermal growth factor receptor-mutated lung adenocarcinoma: case report and literature review. Front Oncol. 2021;11:642190. https:\/\/doi.org\/10.3389\/fonc.2021.642190.","journal-title":"Front Oncol"},{"key":"2353_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70838","volume":"14","author":"J Tan","year":"2025","unstructured":"Tan J, Zhao D, Wang Q, Peng Y, Li J, Li X, et al. Whole exome sequencing study identifies distinct characteristics of transformed small cell lung cancer with EGFR mutation compared to de novo small cell and primary non-small cell lung cancers. Cancer Med. 2025;14:e70838. https:\/\/doi.org\/10.1002\/cam4.70838.","journal-title":"Cancer Med"},{"key":"2353_CR115","doi-asserted-by":"publisher","first-page":"100623","DOI":"10.1016\/j.jtocrr.2023.100623","volume":"5","author":"B Zhang","year":"2024","unstructured":"Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, et al. Brief report: comprehensive clinicogenomic profiling of small cell transformation from EGFR-mutant NSCLC informs potential therapeutic targets. JTO Clin Res Rep. 2024;5:100623. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100623.","journal-title":"JTO Clin Res Rep"},{"key":"2353_CR116","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/cad.0000000000001686","volume":"36","author":"L Kuang","year":"2025","unstructured":"Kuang L, Wang P, Zhou L, Li Y. Transformation of lung adenocarcinoma to small cell lung cancer following osimertinib treatment: a case report and literature review. Anticancer Drugs. 2025;36:253\u20139. https:\/\/doi.org\/10.1097\/cad.0000000000001686.","journal-title":"Anticancer Drugs"},{"key":"2353_CR117","doi-asserted-by":"publisher","first-page":"287","DOI":"10.21037\/tlcr-24-830","volume":"14","author":"J Lasvergnas","year":"2025","unstructured":"Lasvergnas J, Monnet I, Auliac J-B, Rousseau-Bussac G, Chouaid C, Assi\u00e9 J-B. Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report. Transl Lung Cancer Res. 2025;14:287\u201391. https:\/\/doi.org\/10.21037\/tlcr-24-830.","journal-title":"Transl Lung Cancer Res"},{"key":"2353_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.05.006","volume":"94","author":"G Giaccone","year":"2023","unstructured":"Giaccone G, He Y. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer. Semin Cancer Biol. 2023;94:1\u201310. https:\/\/doi.org\/10.1016\/j.semcancer.2023.05.006.","journal-title":"Semin Cancer Biol."},{"key":"2353_CR119","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","volume":"16","author":"MG Oser","year":"2015","unstructured":"Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(14)71180-5.","journal-title":"Lancet Oncol"},{"key":"2353_CR120","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19:499\u2013514. https:\/\/doi.org\/10.1038\/s41571-022-00639-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"2353_CR121","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jtho.2018.08.2028","volume":"14","author":"L Ferrer","year":"2019","unstructured":"Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, et al. A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics. J Thorac Oncol. 2019;14:130\u20134. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2028.","journal-title":"J Thorac Oncol"},{"key":"2353_CR122","doi-asserted-by":"publisher","first-page":"1395654","DOI":"10.3389\/fonc.2024.1395654","volume":"14","author":"R Chen","year":"2024","unstructured":"Chen R, Jian Y, Liu Y, Xie J. ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report. Front Oncol. 2024;14:1395654. https:\/\/doi.org\/10.3389\/fonc.2024.1395654.","journal-title":"Front Oncol"},{"key":"2353_CR123","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.rmcr.2017.03.019","volume":"21","author":"T Imakita","year":"2017","unstructured":"Imakita T, Fujita K, Kanai O, Terashima T, Mio T. Small cell lung cancer transformation during immunotherapy with nivolumab: a case report. Respir Med Case Rep. 2017;21:52\u20135. https:\/\/doi.org\/10.1016\/j.rmcr.2017.03.019.","journal-title":"Respir Med Case Rep"},{"key":"2353_CR124","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/1759-7714.13312","volume":"11","author":"X Si","year":"2020","unstructured":"Si X, You Y, Zhang X, Wang H, Wang M, Zhang L. Histologic transformation of lung cancer during pembrolizumab therapy: a case report. Thorac Cancer. 2020;11:793\u20136. https:\/\/doi.org\/10.1111\/1759-7714.13312.","journal-title":"Thorac Cancer"},{"key":"2353_CR125","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.jtho.2018.11.031","volume":"14","author":"WT Iams","year":"2019","unstructured":"Iams WT, Beckermann KE, Almodovar K, Hernandez J, Vnencak-Jones C, Lim LP, et al. Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS-mutant lung adenocarcinoma: a report of two cases. J Thorac Oncol. 2019;14:e45\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2018.11.031.","journal-title":"J Thorac Oncol"},{"key":"2353_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000697","author":"K Sehgal","year":"2020","unstructured":"Sehgal K, Varkaris A, Viray H, VanderLaan PA, Rangachari D, Costa DB. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000697.","journal-title":"J Immunother Cancer"},{"key":"2353_CR127","doi-asserted-by":"publisher","first-page":"1275957","DOI":"10.3389\/fimmu.2023.1275957","volume":"14","author":"J Zeng","year":"2023","unstructured":"Zeng J, Ding X, Ding J, Wang X. Histological transformation into SCLC: an important resistance mechanism of NSCLC upon immunotherapy. Front Immunol. 2023;14:1275957. https:\/\/doi.org\/10.3389\/fimmu.2023.1275957.","journal-title":"Front Immunol"},{"key":"2353_CR128","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2019.09.025","volume":"138","author":"J Bar","year":"2019","unstructured":"Bar J, Ofek E, Barshack I, Gottfried T, Zadok O, Kamer I, et al. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer. 2019;138:109\u201315. https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.025.","journal-title":"Lung Cancer"},{"key":"2353_CR129","doi-asserted-by":"publisher","first-page":"1691980","DOI":"10.3389\/fimmu.2025.1691980","volume":"16","author":"X Shi","year":"2025","unstructured":"Shi X, Deng W, Pan Y, Chen Y, Wang Y, Wu J. Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy. Front Immunol. 2025;16:1691980. https:\/\/doi.org\/10.3389\/fimmu.2025.1691980.","journal-title":"Front Immunol"},{"key":"2353_CR130","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.18.01585","volume":"37","author":"N Marcoux","year":"2019","unstructured":"Marcoux N, Gettinger SN, O\u2019Kane G, Arbour KC, Neal JW, Husain H, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37:278\u201385. https:\/\/doi.org\/10.1200\/JCO.18.01585.","journal-title":"J Clin Oncol"},{"key":"2353_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102602","volume":"119","author":"I Attili","year":"2023","unstructured":"Attili I, Passaro A, Corvaja C, Trillo Aliaga P, Del Signore E, Spitaleri G, et al. Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: a systematic review. Cancer Treat Rev. 2023;119:102602. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102602.","journal-title":"Cancer Treat Rev"},{"key":"2353_CR132","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00907","volume":"9","author":"L Huang","year":"2025","unstructured":"Huang L, Zhang S, Sun L, Ma J, Han C. Immune checkpoint inhibitors in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant chemotherapy-na\u00efve advanced non-small cell lung cancer: a meta-analysis based on eight randomized trials. JCO Precis Oncol. 2025;9:e2400907. https:\/\/doi.org\/10.1200\/PO-24-00907.","journal-title":"JCO Precis Oncol"},{"key":"2353_CR133","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723\u201333. https:\/\/doi.org\/10.1200\/JCO.20.01605.","journal-title":"J Clin Oncol"},{"key":"2353_CR134","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","volume":"16","author":"RS Herbst","year":"2021","unstructured":"Herbst RS, Garon EB, Kim D-W, Cho BC, Gervais R, Perez-Gracia JL, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16:1718\u201332. https:\/\/doi.org\/10.1016\/j.jtho.2021.05.001.","journal-title":"J Thorac Oncol"},{"key":"2353_CR135","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12:403\u20137. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.007.","journal-title":"J Thorac Oncol"},{"key":"2353_CR136","doi-asserted-by":"publisher","first-page":"8565","DOI":"10.1200\/jco.2024.42.16_suppl.8565","volume":"42","author":"MF Chen","year":"2024","unstructured":"Chen MF, Rakhade S, Quintanal-Villalonga A, Lee J, Forsythe B, Moses KA, et al. Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations. J Clin Oncol. 2024;42:8565\u20138565. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.8565.","journal-title":"J Clin Oncol"},{"key":"2353_CR137","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.3390\/cancers15164016","volume":"15","author":"SR Patel","year":"2023","unstructured":"Patel SR, Das M. Small cell lung cancer: emerging targets and strategies for precision therapy. Cancers (Basel). 2023;15:4016. https:\/\/doi.org\/10.3390\/cancers15164016.","journal-title":"Cancers (Basel)"},{"key":"2353_CR138","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"M-E Goebeler","year":"2020","unstructured":"Goebeler M-E, Bargou RCT. T cell-engaging therapies\u2014BiTEs and beyond. Nat Rev Clin Oncol. 2020;17:418\u201334. https:\/\/doi.org\/10.1038\/s41571-020-0347-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"2353_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101461","author":"AA Khosla","year":"2023","unstructured":"Khosla AA, Jatwani K, Singh R, Reddy A, Jaiyesimi I, Desai A. Bispecific antibodies in lung cancer: a state-of-the-art review. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16101461.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2353_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129855","volume":"24","author":"H Arasanz","year":"2023","unstructured":"Arasanz H, Chocarro L, Fern\u00e1ndez-Rubio L, Blanco E, Bocanegra A, Echaide M, et al. Current indications and future landscape of bispecific antibodies for the treatment of lung cancer. Int J Mol Sci. 2023;24:9855. https:\/\/doi.org\/10.3390\/ijms24129855.","journal-title":"Int J Mol Sci"},{"key":"2353_CR141","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, G\u00fcm\u00fc\u015f M, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393:349\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2502099.","journal-title":"N Engl J Med"},{"key":"2353_CR142","unstructured":"ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06211036. Accessed 2 Feb 2026."},{"key":"2353_CR143","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO-25-00363","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed MF, Alese OB, et al. Phase I dose-escalation results for the delta-like ligand 3\/CD3 IgG-Like T-cell engager obrixtamig (BI 764532) in patients with delta-like ligand 3+ small cell lung cancer or neuroendocrine carcinomas. J Clin Oncol. 2025;43:3021\u201331. https:\/\/doi.org\/10.1200\/JCO-25-00363.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2353_CR144","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jtho.2024.09.060","volume":"19","author":"NJ Choudhury","year":"2024","unstructured":"Choudhury NJ, Beltran H, Johnson ML, Schenk EL, Sanborn RE, Thompson JR, Mamdani H, Dowlati A, Aggarwal RR, Gramza AW, Jain P. OA10.06 Impact of brain metastases on safety and efficacy of MK-6070, a DLL3-targeting T cell engager, in small cell lung cancer. J Thorac Oncol. 2024;19(10):S32\u20133.","journal-title":"J Thorac Oncol"},{"key":"2353_CR145","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8007","author":"YY Zhang","year":"2025","unstructured":"Zhang YY, Zhang T, Yi T, Li M, Yao W, Han L, et al. A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3\/DLL3\/DLL3, as monotherapy in patients with advanced small cell lung cancer. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8007.","journal-title":"J Clin Oncol"},{"key":"2353_CR146","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8094","author":"J Alt","year":"2025","unstructured":"Alt J, Bozorgmehr F, Fuchs F, du Rusquec P, Gazzah A, Dulloo S, et al. DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8094.","journal-title":"J Clin Oncol"},{"key":"2353_CR147","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"key":"2353_CR148","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12672-024-01171-1","volume":"15","author":"Y Meng","year":"2024","unstructured":"Meng Y, Wang X, Yang J, Zhu M, Yu M, Li L, et al. Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research. Discov Oncol. 2024;15:327. https:\/\/doi.org\/10.1007\/s12672-024-01171-1.","journal-title":"Discov Oncol"},{"key":"2353_CR149","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1200\/JCO-25-02142","volume":"44","author":"CM Rudin","year":"2026","unstructured":"Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N, et al. Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial. J Clin Oncol. 2026;44:261\u201373. https:\/\/doi.org\/10.1200\/JCO-25-02142.","journal-title":"J Clin Oncol"},{"key":"2353_CR150","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1080\/14796694.2025.2565995","volume":"21","author":"TK Owonikoko","year":"2025","unstructured":"Owonikoko TK, Byers L, Cheng Y, Hayashi H, Paz-Ares L, P\u00e9rol M, et al. IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. Future Oncol. 2025;21:3275\u201382. https:\/\/doi.org\/10.1080\/14796694.2025.2565995.","journal-title":"Future Oncol"},{"key":"2353_CR151","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","volume":"20","author":"A Dowlati","year":"2025","unstructured":"Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, et al. Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03. J Thorac Oncol. 2025;20:799\u2013808. https:\/\/doi.org\/10.1016\/j.jtho.2024.12.028.","journal-title":"J Thorac Oncol"},{"key":"2353_CR152","doi-asserted-by":"publisher","unstructured":"Byers LA, Chul Cho B, Cooper A, Chiang AC, Han J-Y, Morgensztern D, et al. OA06.04 safety and efficacy of ABBV-706, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in R\/R SCLC. J Thorac Oncol 2025;20:S23. https:\/\/doi.org\/10.1016\/j.jtho.2025.09.049.","DOI":"10.1016\/j.jtho.2025.09.049"},{"key":"2353_CR153","unstructured":"ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT07155174. Accessed 2 Feb 2026."},{"key":"2353_CR154","doi-asserted-by":"publisher","first-page":"106722","DOI":"10.1016\/j.esmoop.2026.106722","volume":"11","author":"F Zhou","year":"2026","unstructured":"Zhou F, Gao Y, Zhou J, Sun L, Yu Y, Huang D, et al. 408O Phase II study of iza-bren (BL-B01D1) in combination with serplulimab in patients with small cell lung cancer (SCLC). ESMO Open. 2026;11:106722. https:\/\/doi.org\/10.1016\/j.esmoop.2026.106722.","journal-title":"ESMO Open"},{"key":"2353_CR155","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1758834009338633","volume":"1","author":"JSW Lind","year":"2009","unstructured":"Lind JSW, Smit EF. Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Ther Adv Med Oncol. 2009;1:95\u2013107. https:\/\/doi.org\/10.1177\/1758834009338633.","journal-title":"Ther Adv Med Oncol"},{"key":"2353_CR156","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.21037\/atm-21-963","volume":"9","author":"J He","year":"2021","unstructured":"He J, Pan H, He J, Li S. Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis. Ann Transl Med. 2021;9:1285. https:\/\/doi.org\/10.21037\/atm-21-963.","journal-title":"Ann Transl Med"},{"key":"2353_CR157","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1200\/jco.2024.42.16_suppl.8001","volume":"42","author":"Y Ohe","year":"2024","unstructured":"Ohe Y, Han B, Nishio M, Watanabe S, Ren X, Murakami S, et al. BEAT-SC: a randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol. 2024;42:8001\u20138001. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.8001.","journal-title":"J Clin Oncol"},{"key":"2353_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.10.013","author":"Z Chen","year":"2025","unstructured":"Chen Z, Wu L, Wang Q, Yu Y, Liu X, Ma R, et al. Brief report: ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage SCLC: results of a phase 1b clinical trial. J Thorac Oncol. 2025. https:\/\/doi.org\/10.1016\/j.jtho.2024.10.013.","journal-title":"J Thorac Oncol"},{"key":"2353_CR159","doi-asserted-by":"publisher","first-page":"655316","DOI":"10.3389\/fonc.2021.655316","volume":"11","author":"A Montanino","year":"2021","unstructured":"Montanino A, Manzo A, Carillio G, Palumbo G, Esposito G, Sforza V, et al. Angiogenesis inhibitors in small cell lung cancer. Front Oncol. 2021;11:655316. https:\/\/doi.org\/10.3389\/fonc.2021.655316.","journal-title":"Front Oncol"},{"key":"2353_CR160","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129:904\u201316. https:\/\/doi.org\/10.1038\/s41416-023-02326-7.","journal-title":"Br J Cancer"},{"key":"2353_CR161","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137. https:\/\/doi.org\/10.1038\/nature03443.","journal-title":"Nature"},{"key":"2353_CR162","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321. https:\/\/doi.org\/10.1038\/nature03445.","journal-title":"Nature"},{"key":"2353_CR163","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.21037\/jtd.2020.03.89","volume":"12","author":"R Barayan","year":"2020","unstructured":"Barayan R, Ran X, Lok BH. PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches. J Thorac Dis. 2020;12:6240\u201352. https:\/\/doi.org\/10.21037\/jtd.2020.03.89.","journal-title":"J Thorac Dis"},{"key":"2353_CR164","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.18.00264","volume":"37","author":"TK Owonikoko","year":"2019","unstructured":"Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL3rd 3rd, Srkalovic G, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37:222\u20139. https:\/\/doi.org\/10.1200\/JCO.18.00264.","journal-title":"J Clin Oncol"},{"key":"2353_CR165","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","volume":"2","author":"LA Byers","year":"2012","unstructured":"Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798\u2013811. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0112.","journal-title":"Cancer Discov"},{"key":"2353_CR166","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","volume":"23","author":"BH Lok","year":"2017","unstructured":"Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res. 2017;23:523\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1040.","journal-title":"Clin Cancer Res"},{"key":"2353_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100874","volume":"42","author":"S Pratama","year":"2024","unstructured":"Pratama S, Wiyono L, Setiawan MS, Lauren BC. PARP inhibitors as therapy for small cell lung carcinoma: a systematic review and meta-analysis of clinical trials. Cancer Treat Res Commun. 2024;42: 100874. https:\/\/doi.org\/10.1016\/j.ctarc.2025.100874.","journal-title":"Cancer Treat Res Commun."},{"key":"2353_CR168","doi-asserted-by":"publisher","first-page":"eadh2579","DOI":"10.1126\/sciadv.adh2579","volume":"10","author":"C Kim","year":"2024","unstructured":"Kim C, Wang X-D, Liu Z, Hao J, Wang S, Li P, et al. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Sci Adv. 2024;10:eadh2579. https:\/\/doi.org\/10.1126\/sciadv.adh2579.","journal-title":"Sci Adv"},{"key":"2353_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040727","author":"EH Knelson","year":"2021","unstructured":"Knelson EH, Patel SA, Sands JM. PARP inhibitors in small-cell lung cancer: rational combinations to improve responses. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040727.","journal-title":"Cancers (Basel)"},{"key":"2353_CR170","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","volume":"9","author":"AF Farago","year":"2019","unstructured":"Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9:1372\u201387. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0582.","journal-title":"Cancer Discov"},{"key":"2353_CR171","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","volume":"36","author":"MC Pietanza","year":"2018","unstructured":"Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36:2386\u201394. https:\/\/doi.org\/10.1200\/JCO.2018.77.7672.","journal-title":"J Clin Oncol"},{"key":"2353_CR172","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.1073\/pnas.1410419111","volume":"111","author":"A Augustyn","year":"2014","unstructured":"Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA. 2014;111:14788\u201393. https:\/\/doi.org\/10.1073\/pnas.1410419111.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2353_CR173","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136. https:\/\/doi.org\/10.1126\/scitranslmed.aac9459.","journal-title":"Sci Transl Med"},{"key":"2353_CR174","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1038\/s41467-022-31998-7","volume":"13","author":"H-Y Chen","year":"2022","unstructured":"Chen H-Y, Durmaz YT, Li Y, Sabet AH, Vajdi A, Denize T, et al. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1. Nat Commun. 2022;13:4998. https:\/\/doi.org\/10.1038\/s41467-022-31998-7.","journal-title":"Nat Commun"},{"key":"2353_CR175","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu G, Guthrie MR, B\u00f6hm S, Br\u00e4gelmann J, Can I, Ballieu PM, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell. 2017;31:270\u201385. https:\/\/doi.org\/10.1016\/j.ccell.2016.12.005.","journal-title":"Cancer Cell"},{"key":"2353_CR176","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","volume":"15","author":"TK Owonikoko","year":"2020","unstructured":"Owonikoko TK, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, et al. Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses. J Thorac Oncol. 2020;15:274\u201387. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.013.","journal-title":"J Thorac Oncol"},{"key":"2353_CR177","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1101\/gad.314815.118","volume":"32","author":"Y-H Huang","year":"2018","unstructured":"Huang Y-H, Klingbeil O, He X-Y, Wu XS, Arun G, Lu B, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 2018;32:915\u201328. https:\/\/doi.org\/10.1101\/gad.314815.118.","journal-title":"Genes Dev"},{"key":"2353_CR178","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1634\/theoncologist.2016-0220","volume":"21","author":"AA Chiappori","year":"2016","unstructured":"Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, et al. A randomized phase II study of linsitinib (OSI-906) versus topotecan in patients with relapsed small-cell lung cancer. Oncologist. 2016;21:1163\u20134. https:\/\/doi.org\/10.1634\/theoncologist.2016-0220.","journal-title":"Oncologist"},{"key":"2353_CR179","unstructured":"ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06769126 (accessed May 2, 2026)."},{"key":"2353_CR180","doi-asserted-by":"publisher","first-page":"409","DOI":"10.21037\/tlcr.2017.07.05","volume":"6","author":"V Foy","year":"2017","unstructured":"Foy V, Fernandez-Gutierrez F, Faivre-Finn C, Dive C, Blackhall F. The clinical utility of circulating tumour cells in patients with small cell lung cancer. Transl Lung Cancer Res. 2017;6:409\u201317. https:\/\/doi.org\/10.21037\/tlcr.2017.07.05.","journal-title":"Transl Lung Cancer Res"},{"key":"2353_CR181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111597","volume":"9","author":"M Ilie","year":"2014","unstructured":"Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud J-M, Padovani B, et al. \u201cSentinel\u201d circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS ONE. 2014;9:e111597. https:\/\/doi.org\/10.1371\/journal.pone.0111597.","journal-title":"PLoS ONE"},{"key":"2353_CR182","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2353\/ajpath.2009.090078","volume":"175","author":"J-M Hou","year":"2009","unstructured":"Hou J-M, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009;175:808\u201316. https:\/\/doi.org\/10.2353\/ajpath.2009.090078.","journal-title":"Am J Pathol"},{"key":"2353_CR183","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","volume":"30","author":"J-M Hou","year":"2012","unstructured":"Hou J-M, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525\u201332. https:\/\/doi.org\/10.1200\/JCO.2010.33.3716.","journal-title":"J Clin Oncol"},{"key":"2353_CR184","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1093\/annonc\/mds138","volume":"23","author":"TJN Hiltermann","year":"2012","unstructured":"Hiltermann TJN, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJW, et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. 2012;23:2937\u201342. https:\/\/doi.org\/10.1093\/annonc\/mds138.","journal-title":"Ann Oncol"},{"key":"2353_CR185","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.lungcan.2014.05.002","volume":"85","author":"N Normanno","year":"2014","unstructured":"Normanno N, Rossi A, Morabito A, Signoriello S, Bevilacqua S, Di Maio M, et al. Prognostic value of circulating tumor cells\u2019 reduction in patients with extensive small-cell lung cancer. Lung Cancer. 2014;85:314\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2014.05.002.","journal-title":"Lung Cancer"},{"key":"2353_CR186","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2018.04.008","volume":"120","author":"M Du","year":"2018","unstructured":"Du M, Thompson J, Fisher H, Zhang P, Huang C-C, Wang L. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance. Lung Cancer. 2018;120:113\u201321. https:\/\/doi.org\/10.1016\/j.lungcan.2018.04.008.","journal-title":"Lung Cancer"},{"key":"2353_CR187","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jtho.2017.09.1951","volume":"13","author":"K Almodovar","year":"2018","unstructured":"Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, et al. Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse. J Thorac Oncol. 2018;13:112\u201323. https:\/\/doi.org\/10.1016\/j.jtho.2017.09.1951.","journal-title":"J Thorac Oncol"},{"key":"2353_CR188","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ebiom.2016.06.032","volume":"10","author":"L Fernandez-Cuesta","year":"2016","unstructured":"Fernandez-Cuesta L, Perdomo S, Avogbe PH, Leblay N, Delhomme TM, Gaborieau V, et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine. 2016;10:117\u201323. https:\/\/doi.org\/10.1016\/j.ebiom.2016.06.032.","journal-title":"EBioMedicine"},{"key":"2353_CR189","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","volume":"12","author":"D Mathios","year":"2021","unstructured":"Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12:5060. https:\/\/doi.org\/10.1038\/s41467-021-24994-w.","journal-title":"Nat Commun"},{"key":"2353_CR190","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.3390\/cancers15205005","volume":"15","author":"AM Elshoeibi","year":"2023","unstructured":"Elshoeibi AM, Elsayed B, Kaleem MZ, Elhadary MR, Abu-Haweeleh MN, Haithm Y, et al. Proteomic profiling of small-cell lung cancer: a systematic review. Cancers (Basel). 2023;15:5005. https:\/\/doi.org\/10.3390\/cancers15205005.","journal-title":"Cancers (Basel)"},{"key":"2353_CR191","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.21037\/tlcr-2025-317","volume":"14","author":"B Wei","year":"2025","unstructured":"Wei B, Wang W, Geng S, Wu W, Ding C, Zhu D, et al. An effective and affordable blood test for lung cancer early detection using four protein markers and artificial intelligence. Transl Lung Cancer Res. 2025;14:3444\u201356. https:\/\/doi.org\/10.21037\/tlcr-2025-317.","journal-title":"Transl Lung Cancer Res"},{"key":"2353_CR192","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","volume":"9","author":"WJ Petty","year":"2023","unstructured":"Petty WJ, Paz-Ares L. Emerging strategies for the treatment of small cell lung cancer: a review. JAMA Oncol. 2023;9:419\u201329. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5631.","journal-title":"JAMA Oncol"},{"key":"2353_CR193","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40265-019-01240-8","volume":"80","author":"N Reguart","year":"2020","unstructured":"Reguart N, Marin E, Remon J, Reyes R, Teixido C. In search of the long-desired \u201cCopernican therapeutic revolution\u201d in small-cell lung cancer. Drugs. 2020;80:241\u201362. https:\/\/doi.org\/10.1007\/s40265-019-01240-8.","journal-title":"Drugs"},{"key":"2353_CR194","unstructured":"Unveiling drivers of MHC repression and therapeutic strategies to counter immune evasion in small cell lung cancer. ASCO n.d. https:\/\/www.asco.org\/abstracts-presentations\/249077. Accessed 20 Apr 2026."},{"key":"2353_CR195","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S1470-2045(24)00374-7","volume":"26","author":"T Sen","year":"2025","unstructured":"Sen T, Dotsu Y, Corbett V, Puri S, Sen U, Boyle TA, et al. Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies. Lancet Oncol. 2025;26:e13\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(24)00374-7.","journal-title":"Lancet Oncol"},{"key":"2353_CR196","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jtho.2022.05.014","volume":"17","author":"EM Nguyen","year":"2022","unstructured":"Nguyen EM, Taniguchi H, Chan JM, Zhan YA, Chen X, Qiu J, et al. Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC. J Thorac Oncol. 2022;17:1014\u201331. https:\/\/doi.org\/10.1016\/j.jtho.2022.05.014.","journal-title":"J Thorac Oncol"},{"key":"2353_CR197","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.1038\/s41467-025-66800-x","volume":"16","author":"L Meder","year":"2025","unstructured":"Meder L, Orschel CI, Bouchez CL, Gholamipoorfard R, Orschel CV, Stahl D, et al. ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer. Nat Commun. 2025;16:10983. https:\/\/doi.org\/10.1038\/s41467-025-66800-x.","journal-title":"Nat Commun"},{"key":"2353_CR198","doi-asserted-by":"publisher","first-page":"116125","DOI":"10.1016\/j.intimp.2025.116125","volume":"170","author":"Y Cai","year":"2026","unstructured":"Cai Y, Li X, Zhu S, Wu H, Nie J, Huang F. Lactate represses MHC-I antigen presentation via H4K5 lactylation-PRC2 in small cell lung cancer subtype A. Int Immunopharmacol. 2026;170:116125. https:\/\/doi.org\/10.1016\/j.intimp.2025.116125.","journal-title":"Int Immunopharmacol"},{"key":"2353_CR199","doi-asserted-by":"publisher","first-page":"v928","DOI":"10.1093\/annonc\/mdz394.089","volume":"30","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Goldman JW, Garassino MC, Dvorkin M, Trukhin D, Statsenko G, et al. PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: results from CASPIAN. Ann Oncol. 2019;30:v928\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdz394.089.","journal-title":"Ann Oncol"},{"key":"2353_CR200","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-025-02445-y","volume":"10","author":"Y Yang","year":"2025","unstructured":"Yang Y, Wu Y, Zhao J, Zhang T, Fei K, Zhao X, et al. Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients. Signal Transduct Target Ther. 2025;10:347. https:\/\/doi.org\/10.1038\/s41392-025-02445-y.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02353-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02353-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02353-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:03:55Z","timestamp":1788242635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02353-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":200,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2353"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02353-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AJ reports consulting fees from AstraZeneca, Merck, Johnson and Johnson, Regeneron, EMD Serano, and Daiichi Sankyo. NJC reports institutional research funding from Amgen, AbbVie, Monte Rosa Therapeutics, Roche\/Genetech, Merck, Harpoon Therapeutics, Janux Therapeutics, Seagen\/Pfizer, Corbus, DualityBio; Honoraria from MJH Life Sciences, IDEOlogy Health; Royalties from Wolters Kluwer (\n                      Pocket Oncology, 3\n                      \n                        rd\n                      \n                      edition)\n                      ; consulting fees from AbbVie, Merck, Harpoon Therapeutics, Eli Lily, Amgen, Daiichi, Ideaya Biosciences, BMS, Pfizer. SS, MT, KG, HK, WH have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SS, MT, KG, HK, WH, AJ, and NC participated in the conception, writing, editing and approval of this manuscript.","order":7,"name":"Ethics","label":"Authors' contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}